Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 3
2015 1
2016 2
2018 4
2019 2
2020 1
2021 5
2022 4
2023 4
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Results by year

Filters applied: . Clear all
Page 1
Mechanical computing.
Yasuda H, Buskohl PR, Gillman A, Murphey TD, Stepney S, Vaia RA, Raney JR. Yasuda H, et al. Among authors: gillman a. Nature. 2021 Oct;598(7879):39-48. doi: 10.1038/s41586-021-03623-y. Epub 2021 Oct 6. Nature. 2021. PMID: 34616053 Review.
Origami mechanologic.
Treml B, Gillman A, Buskohl P, Vaia R. Treml B, et al. Among authors: gillman a. Proc Natl Acad Sci U S A. 2018 Jul 3;115(27):6916-6921. doi: 10.1073/pnas.1805122115. Epub 2018 Jun 18. Proc Natl Acad Sci U S A. 2018. PMID: 29915077 Free PMC article.
Biologics (mepolizumab and omalizumab) induced remission in severe asthma patients.
Thomas D, McDonald VM, Stevens S, Harvey ES, Baraket M, Bardin P, Bowden JJ, Bowler S, Chien J, Chung LP, Gillman A, Hew M, Hodge S, James A, Jenkins C, Katelaris CH, Katsoulotos GP, Langton D, Lee J, Marks G, Peters M, Radhakrishna N, Reynolds PN, Rimmer J, Sivakumaran P, Upham JW, Wark P, Yang IA, Gibson PG. Thomas D, et al. Among authors: gillman a. Allergy. 2024 Feb;79(2):384-392. doi: 10.1111/all.15867. Epub 2023 Aug 25. Allergy. 2024. PMID: 37632144
Comorbidities Modify the Phenotype but Not the Treatment Effectiveness to Mepolizumab in Severe Eosinophilic Asthma.
Kritikos V, Harvey ES, Stevens S, Katelaris CH, Langton D, Rimmer J, Farah CS, Gillman A, Hew M, Radhakrishna N, Thomas D, Gibson PG; Australian Mepolizumab Registry Investigators. Kritikos V, et al. Among authors: gillman a. J Allergy Clin Immunol Pract. 2023 Mar;11(3):885-895.e13. doi: 10.1016/j.jaip.2022.12.004. Epub 2022 Dec 23. J Allergy Clin Immunol Pract. 2023. PMID: 36572182
Thunderstorm asthma in seasonal allergic rhinitis: The TAISAR study.
Douglass JA, Lodge C, Chan S, Doherty A, Tan JA, Jin C, Stewart A, Southcott AM, Gillman A, Lee J, Csutoros D, Hannan L, Ruane L, Barnes S, Irving L, Harun NS, Lachapelle P, Spriggs K, Sutherland M, See K, McDonald CF, Conron M, Radhakrishna N, Worsnop C, Johnston FH, Davies JM, Bryant V, Iles L, Ranson D, Spanos P, Vicendese D, Lowe A, Newbigin EJ, Bardin P, Dharmage S. Douglass JA, et al. Among authors: gillman a. J Allergy Clin Immunol. 2022 May;149(5):1607-1616. doi: 10.1016/j.jaci.2021.10.028. Epub 2021 Nov 11. J Allergy Clin Immunol. 2022. PMID: 34774618
Asthma in the elderly.
Gillman A, Douglass JA. Gillman A, et al. Asia Pac Allergy. 2012 Apr;2(2):101-8. doi: 10.5415/apallergy.2012.2.2.101. Epub 2012 Apr 30. Asia Pac Allergy. 2012. PMID: 22701859 Free PMC article.
Mepolizumab effectiveness and identification of super-responders in severe asthma.
Harvey ES, Langton D, Katelaris C, Stevens S, Farah CS, Gillman A, Harrington J, Hew M, Kritikos V, Radhakrishna N, Bardin P, Peters M, Reynolds PN, Upham JW, Baraket M, Bowler S, Bowden J, Chien J, Chung LP, Grainge C, Jenkins C, Katsoulotos GP, Lee J, McDonald VM, Reddel HK, Rimmer J, Wark PAB, Gibson PG. Harvey ES, et al. Among authors: gillman a. Eur Respir J. 2020 May 21;55(5):1902420. doi: 10.1183/13993003.02420-2019. Print 2020 May. Eur Respir J. 2020. PMID: 32139455 Free article.
Mepolizumab improvements in health-related quality of life and disease symptoms in a patient population with very severe chronic rhinosinusitis with nasal polyps: psychometric and efficacy analyses from the SYNAPSE study.
Fokkens W, Trigg A, Lee SE, Chan RH, Diamant Z, Hopkins C, Howarth P, Lund V, Mayer B, Sousa AR, Yancey S, Tabberer M; SYNAPSE study group. Fokkens W, et al. J Patient Rep Outcomes. 2023 Jan 20;7(1):4. doi: 10.1186/s41687-023-00543-5. J Patient Rep Outcomes. 2023. PMID: 36662344 Free PMC article. Clinical Trial.
21 results